Extracellular Vesicles in Cancer Diagnosis and Therapy: Advances, Challenges, and Prospects for Clinical Translation
International Journal of Molecular Sciences · 28.02.2026 · 27 (5) · 2280
DOI: 10.3390/ijms27052280 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.02.2026. Verfasst von Lingyu Kong und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Sports, Shenyang Ligong University, Shenyang 110159, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Doctoral Research Start-up Fund of Shenyang University of Technology.
Abstract (Originalsprache)
Extracellular vesicles (EVs) have emerged as promising tools for cancer diagnosis and therapy owing to their excellent biocompatibility, low immunogenicity, and ability to transport diverse bioactive molecules. This review summarizes recent advances in EVs research, focusing on isolation and detection technologies, their diagnostic and therapeutic applications in oncology, and the key challenges limiting clinical translation. Conventional EVs isolation methods, including ultracentrifugation, density-gradient centrifugation, and polymer-based precipitation, are discussed alongside emerging strategies such as immunoaffinity enrichment, microfluidic separation, lipid-mediated isolation, and thermophoretic enrichment, with comparative evaluation of their yield, purity, cost, and scalability. In cancer diagnosis, EV-associated biomolecules, such as miRNAs, mRNAs, proteins, and lncRNAs, show strong potential as liquid biopsy biomarkers for noninvasive early detection and dynamic disease monitoring. In therapeutic contexts, EVs serve as versatile carriers for gene molecules, chemotherapeutic agents, and small-molecule drugs, and can enhance immunotherapy and RNA-based treatments. Importantly, EVs released from metabolically active tissues, particularly skeletal muscle, contribute to systemic immune regulation and metabolic homeostasis, and their biogenesis and molecular cargo can be influenced by physical activity and exercise-related nutritional status. These insights highlight the need to integrate microengineering technologies, biomolecular profiling, standardized manufacturing systems, and lifestyle-related factors such as exercise and nutrition to accelerate the clinical translation of EV-based strategies in precision oncology and regenerative medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Sports, Shenyang Ligong University, Shenyang 110159, China.
- School of Information Science and Engineering, Shenyang Ligong University, Shenyang 110159, China.
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Doctoral Research Start-up Fund of Shenyang University of Technology
- Liaoning Provincial Department of Education Basic Research Project Youth Project
- National Key R&D Program of China
Zitieren
APA
Kong, L., Zhao, G., Wu, X., & Ma, S. (2026). Extracellular Vesicles in Cancer Diagnosis and Therapy: Advances, Challenges, and Prospects for Clinical Translation. International Journal of Molecular Sciences, 27(5), 2280. https://doi.org/10.3390/ijms27052280
Vancouver
Kong L, Zhao G, Wu X, Ma S. Extracellular Vesicles in Cancer Diagnosis and Therapy: Advances, Challenges, and Prospects for Clinical Translation. International Journal of Molecular Sciences. 2026;27(5):2280. doi:10.3390/ijms27052280
BibTeX
@article{Kong2026,
author = {Kong, Lingyu and Zhao, Guangyu and Wu, Xinwei and Ma, Shuang},
title = {Extracellular Vesicles in Cancer Diagnosis and Therapy: Advances, Challenges, and Prospects for Clinical Translation},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {5},
pages = {2280},
doi = {10.3390/ijms27052280}
}
EUVIMED